Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Univariate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Univariate. Displaying page 1 of 1.
    EudraCT Number: 2021-005094-28 Sponsor Protocol Number: VAC3_COVID-19_antibody_study_V1 Start Date*: 2021-10-21
    Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology
    Full Title: Population-based prospective, clinical study on efficacy and safety of a booster COVID-19 vaccination
    Medical condition: SARS-CoV-2 infection prevention
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005601-37 Sponsor Protocol Number: RBHP2015PICKERING4 Start Date*: 2016-02-24
    Sponsor Name:CHU Clermont-Ferrand
    Full Title: IMPACT OF 5% LIDOCAINE MEDICATED PLASTER ON ALLODYNIC SYMPTOMS OF LOCALIZED NEUROPATHIC PAIN AFTER KNEE SURGERY. A prospective, randomized, placebo controlled study in parallel groups.
    Medical condition: Post operative neuropathic pain (PONP)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003831-21 Sponsor Protocol Number: 2277/2007 Start Date*: 2007-07-18
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: PHARMACOKINETIC PERSPECTIVE STUDY IN COLORECTAL CANCER PATIENTS AND CANDIDATE FOR FLUOROPYRIMIDINE THERAPY: 5-FLUORO TEST
    Medical condition: Colo-rectal adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002258-60 Sponsor Protocol Number: UMCN-ONCO-201302 Start Date*: 2013-08-30
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000640-64 Sponsor Protocol Number: MOU-2020-01 Start Date*: 2020-05-26
    Sponsor Name:Masarykův onkologický ústav
    Full Title: 11C-METHIONIN IN DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH AGGRESSIVE GLIOBLASTOM SHOWING A TIME POST-OPERATING PROGRESS BEFORE INITIATING ADJUVANT ONCOLOGICAL TREATMENT
    Medical condition: REP (rapid early progression) after glioblastoma operation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004487-53 Sponsor Protocol Number: 2312/2007 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration.
    Medical condition: Exudative and atrophic age-related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006713-16 Sponsor Protocol Number: CP12-0604 Start Date*: 2008-09-02
    Sponsor Name:ImClone Systems Incorporated
    Full Title: Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma
    Medical condition: Metastatic Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000266-11 Sponsor Protocol Number: 2012-772 Start Date*: 2014-05-27
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.
    Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery.
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004210-10 Sponsor Protocol Number: ASSTBS-BLADE-2540-2016 Start Date*: 2017-03-29
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: A PILOT PHASE IV STUDY TO EVALUATE VARIATION IN BONE MINERAL DENSITY, LEAN AND FAT BODY MASS MEASURED BY DUAL-ENERGY X-RAY ABSORPTIOMETRY IN PATIENTS WITH PROSTATE CANCER WITHOUT BONE METASTASIS T...
    Medical condition: prostate cancer prostate cancer without bone metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005911-82 Sponsor Protocol Number: AL0506st Start Date*: 2007-04-02
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter, placebo-controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children w...
    Medical condition: IgE-mediated allergic disease manifested as symptoms of allergic rhinitis/rhinoconjunctivitis with or without allergic bronchial asthma (GINA I und II) triggered by grass pollen allergens.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005214-11 Sponsor Protocol Number: GBG-68 Start Date*: 2012-08-10
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Neo- / adjuvant phase III trial to compare intense dose-dense chemotherapy to tailored dose-dense chemotherapy in patients with high-risk early breast cancer (GAIN-2 trial)
    Medical condition: Patients with primary breast cancer (now in neoadjuvant or adjuvant setting).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003330-16 Sponsor Protocol Number: GBG74 Start Date*: 2013-02-26
    Sponsor Name:GBG Forschungs GmbH (German Breast Group)
    Full Title: Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or lum...
    Medical condition: Breast Cancer in patients with operable Triple Negative or luminal B/HER2 normal patients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 13:09:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA